{"id":393,"date":"2024-12-24T10:00:00","date_gmt":"2024-12-24T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=393"},"modified":"2025-10-21T05:09:47","modified_gmt":"2025-10-21T05:09:47","slug":"china-bd-2024-jemincare-and-rapt-therapeutics-enters-a-708-million-usd-license-for-anti-ige-monoclonal-antibody-jyb1904-rpt904","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/393.html","title":{"rendered":"[China BD 2024] Jemincare and RAPT Therapeutics Enters a 708 million USD License for anti-IgE Monoclonal Antibody JYB1904 (RPT904)"},"content":{"rendered":"\n

Announced Date: 2024-12-23 (December 23, 2024)<\/p>\n\n\n\n

Asset Name: JYB1904 (RPT904)<\/p>\n\n\n\n

Licensor (Seller): Shanghai Jemincare Pharmaceutical (China)<\/p>\n\n\n\n

Licensee (Buyer): RAPT Therapeutics (US)<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Asset Modality: monoclonal antibody (mAb)<\/p>\n\n\n\n

Asset Target: anti-immunoglobulin E (IgE) <\/p>\n\n\n\n

Potential Indication: several allergic disorders and allergic inflammatory diseases<\/p>\n\n\n\n

Currently Stage <During The BD>: conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Scope of Authority:<\/p>\n\n\n\n

RAPT is granted worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan (together, the \u201cJemincare Territory\u201d) to develop and commercialize RPT904.\u00a0<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Payment Detail:<\/p>\n\n\n\n

Jemincare\u00a0 will receive:<\/p>\n\n\n\n

Upfront payment $35 million,<\/p>\n\n\n\n

Development, regulatory, and commercial milestones payment up to $672.5 million.<\/p>\n\n\n\n

Royalties on future sales of RPT904 outside the Jemincare Territory.\u00a0<\/p>\n\n\n\n

.<\/p>\n\n\n\n

Link:<\/p>\n\n\n\n

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody – RAPT Therapeutics<\/a><\/p>\n\n\n\n

.<\/p>\n\n\n\n

Note:<\/p>\n\n\n\n

Shanghai Jemincare Pharmaceutical, a subsidiary of Jiangxi Jemincare Group \u4e0a\u6d77\u6d4e\u715c\u533b\u836f\uff0c\u6c5f\u897f\u6d4e\u6c11\u53ef\u4fe1\u5b50\u516c\u53f8<\/p>\n","protected":false},"excerpt":{"rendered":"

Announced Date: 2024-12-23 (December 23, 2024) Asset Name: JYB1904 (RPT904) Licensor (Seller): Shanghai Jemincare Pharmaceutical (China) … [China BD 2024] Jemincare and RAPT Therapeutics Enters a 708 million USD License for anti-IgE Monoclonal Antibody JYB1904 (RPT904)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-393","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=393"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/393\/revisions"}],"predecessor-version":[{"id":394,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/393\/revisions\/394"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}